Results 181 to 190 of about 79,448 (358)
Survivin and Aurora Kinase A control cell fate decisions during mitosis
Molecular Oncology, EarlyView.Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir +2 more
wiley +1 more source
Extemporaneous Formulations for Pediatric Patients: Global Necessities, Challenges and Opportunities. [PDF]
PharmaceuticsPai VB, Nahata MC.
europepmc +1 more source
A Web Scraping of Chemical Compounds with an Anti-Drug Feature Using IoT
, 2022 Nadia Mahmood Hussien +1 more
openalex +2 more sources
Molecular Oncology, EarlyView.CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Mistaken Administration of Hydroxyurea Instead of Tacrolimus in a Pediatric Kidney Transplant Recipient: A Case Report. [PDF]
J Pediatr Pharmacol TherLafond S +4 more
europepmc +1 more source
Prevalence of subjective symptoms among hospital pharmacists and association with drug compounding practices. [PDF]
Ind Health, 2015 Inaba R +4 more
europepmc +1 more source